Paz-Ares L - Search Results

1

Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy.

Diaz-Cano I, Paz-Ares L, Otano I. Diaz-Cano I, et al. Int Rev Cell Mol Biol. 2022;370:163-192. doi: 10.1016/bs.ircmb.2022.04.003. Epub 2022 May 23. Int Rev Cell Mol Biol. 2022. PMID: 35798505 Review.

2

At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC.

Otano I, Ucero AC, Zugazagoitia J, Paz-Ares L. Otano I, et al. Nat Rev Clin Oncol. 2023 Mar;20(3):143-159. doi: 10.1038/s41571-022-00718-x. Epub 2023 Jan 13. Nat Rev Clin Oncol. 2023. PMID: 36639452 Review.

3

Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options.

Zugazagoitia J, Paz-Ares L. Zugazagoitia J, et al. J Clin Oncol. 2022 Feb 20;40(6):671-680. doi: 10.1200/JCO.21.01881. Epub 2022 Jan 5. J Clin Oncol. 2022. PMID: 34985925 Review.

4

Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis.

Yarza R, Bover M, Herrera-Juarez M, Rey-Cardenas M, Paz-Ares L, Lopez-Martin JA, Haanen J. Yarza R, et al. Oncologist. 2023 Jun 2;28(6):e406-e415. doi: 10.1093/oncolo/oyad078. Oncologist. 2023. PMID: 37036865 Free PMC article.

5

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.

Bonomi PD, Gandara D, Hirsch FR, Kerr KM, Obasaju C, Paz-Ares L, Bellomo C, Bradley JD, Bunn PA Jr, Culligan M, Jett JR, Kim ES, Langer CJ, Natale RB, Novello S, Pérol M, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Vansteenkiste JF, Wakelee H, Thatcher N. Bonomi PD, et al. Ann Oncol. 2018 Aug 1;29(8):1701-1709. doi: 10.1093/annonc/mdy196. Ann Oncol. 2018. PMID: 29905778 Free PMC article. Review.

6

Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.

Isla D, de Castro J, García-Campelo R, Lianes P, Felip E, Garrido P, Paz-Ares L, Trigo JM. Isla D, et al. Clin Transl Oncol. 2020 May;22(5):759-771. doi: 10.1007/s12094-019-02191-y. Epub 2019 Jul 31. Clin Transl Oncol. 2020. PMID: 31368078 Free article.

7

Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.

Heitzer E, van den Broek D, Denis MG, Hofman P, Hubank M, Mouliere F, Paz-Ares L, Schuuring E, Sültmann H, Vainer G, Verstraaten E, de Visser L, Cortinovis D. Heitzer E, et al. ESMO Open. 2022 Apr;7(2):100399. doi: 10.1016/j.esmoop.2022.100399. Epub 2022 Feb 21. ESMO Open. 2022. PMID: 35202954 Free PMC article. Review.

8

Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review.

Petty WJ, Paz-Ares L. Petty WJ, et al. JAMA Oncol. 2023 Mar 1;9(3):419-429. doi: 10.1001/jamaoncol.2022.5631. JAMA Oncol. 2023. PMID: 36520421 Review.

9

Targeted therapy for lung cancer: Beyond EGFR and ALK.

Herrera-Juárez M, Serrano-Gómez C, Bote-de-Cabo H, Paz-Ares L. Herrera-Juárez M, et al. Cancer. 2023 Jun 15;129(12):1803-1820. doi: 10.1002/cncr.34757. Epub 2023 Apr 19. Cancer. 2023. PMID: 37073562 Review.

10

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.

Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Westover D, et al. Ann Oncol. 2018 Jan 1;29(suppl_1):i10-i19. doi: 10.1093/annonc/mdx703. Ann Oncol. 2018. PMID: 29462254 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

458 results

Search Page